Likewise, the levels of HMGN1 in the serum of NSCLC individuals were higher in non-metastatic stages (I-III) as compared to the metastatic stage (IV), suggesting that HMGN1 can serve as a biomarker for early stages of NSCLC [49]. This evidence concerns the gene HMGN1 and non-small cell lung carcinoma.